

## Chapter CSB 2

ADDITIONS TO SCHEDULES IN SS. 961.14,  
961.16, 961.18, 961.20 AND 961.22, STATS.

CSB 2.01	Addition of methaqualone to schedule II.	CSB 2.49	Addition of U-47700 to schedule I.
CSB 2.02	Addition of benzphetamine, chlorphentermine, clortermine, mazindol, and phendimetrazine to schedule III.	CSB 2.50	Addition of AB-CHMINACA, AB-PINACA and THJ-2201 to schedule I.
CSB 2.03	Addition of fenfluramine to schedule IV.	CSB 2.51	Addition of MAB-CHMINACA to schedule I.
CSB 2.04	Addition of amobarbital, pentobarbital, and secobarbital to schedule II; retention of certain forms of amobarbital, pentobarbital and secobarbital in schedule III.	CSB 2.52	Addition of 4-MePPP and a-PBP to schedule I.
CSB 2.05	Addition of drotebanol to schedule I.	CSB 2.53	Scheduling of acryl fentanyl.
CSB 2.06	Addition of pentazocine to schedule III.	CSB 2.54	Addition of oral solutions containing dronabinol to schedule II.
CSB 2.07	Transfer of hydrochloride form of etorphine from schedule I to schedule II.	CSB 2.55	Addition of 5F-ADB, 5F-AB, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA to schedule I.
CSB 2.08	Addition of poppy straw to schedule II, addition of pemoline and mebutamate to schedule IV.	CSB 2.56	Addition of 4-fluoroisobutyryl fentanyl to schedule I.
CSB 2.09	Additions to schedules IV and I.	CSB 2.57	Scheduling of cyclopropyl fentanyl.
CSB 2.10	Addition of propiram to schedule I.	CSB 2.58	Exclusion of naldemedine.
CSB 2.11	Renumbering and addition to schedule IV of diethylpropion and phentermine.	CSB 2.59	Addition of ortho-fluorofentanyl to schedule I.
CSB 2.13	Addition of dextropropoxyphene to schedule IV.	CSB 2.60	Addition of FUB-AMB to schedule I.
CSB 2.14	Addition of prazepam to schedule IV.	CSB 2.61	Addition of MT-45 to schedule I.
CSB 2.15	Addition of parahexyl to schedule I; removal of loperamide from schedule V; addition of triazolam to schedule IV.	CSB 2.62	Addition of para-chloroisobutyryl fentanyl to schedule I.
CSB 2.16	Transfer of sufentanil from schedule I to schedule II.	CSB 2.63	Addition of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA to schedule I.
CSB 2.17	Addition of buprenorphine to schedule V; transfer of methaqualone from schedule II to schedule I; transfer of dronabinol from schedule I to schedule II.	CSB 2.64	Addition of N-Ethylpentylone to schedule I.
CSB 2.18	Addition of 3,4-methylenedioxyamphetamine to schedule I.	CSB 2.65	Addition of approved cannabidiol drugs to schedule V.
CSB 2.19	Additions, deletions and transfers to statutory schedules.	CSB 2.66	Addition of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 to schedule I.
CSB 2.20	Addition of beta-hydroxy-3-methylfentanyl to schedule I.	CSB 2.67	Addition of Brexanolone and Solriamfetol to schedule IV.
CSB 2.21	Additions, deletions, corrections, transfers, and amendments to drug schedules.	CSB 2.68	Addition of N-Ethylhexedrone, a-PHP, 4-MEAP, MPPH, PV8 and 4-chloro-a-PVP to schedule I.
CSB 2.22	Additions to drug schedules.	CSB 2.69	Addition of Noroxymorphone to schedule II.
CSB 2.23	Additions and amendments to drug schedules.	CSB 2.70	Scheduling 4F-MDMB-BINACA and MMB-FUBICA.
CSB 2.24	Addition of butorphanol to schedule IV.	CSB 2.71	Addition of lasmiditan to schedule V.
CSB 2.25	Addition of remifentanyl to schedule II; transfer of dronabinol from schedule II to schedule III; addition of fenproporex, modafinil, sibutramine, zaleplon and zolpidem to schedule IV; spelling correction of carfentanil.	CSB 2.72	Scheduling of isotonitazene and 1P-LSD.
CSB 2.26	Addition of dihydroetorphine to schedule II.	CSB 2.73	Addition of cenobamate to schedule V.
CSB 2.28	Addition of dichloralphenazone to schedule IV.	CSB 2.74	Addition of Lemborexant to schedule IV.
CSB 2.29	Transfer of buprenorphine from schedule V to schedule III.	CSB 2.75	Exclusion of approved cannabidiol drugs from schedule I.
CSB 2.30	Addition of gamma-hydroxybutyric acid to schedule III.	CSB 2.76	Addition of norfentanyl to schedule II.
CSB 2.31	Addition of 2,5 dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) to schedule I.	CSB 2.77	Scheduling of flualprazolam.
CSB 2.32	Addition of N-benzylpiperazine (BZP) to schedule I.	CSB 2.78	Addition of crotonyl fentanyl to schedule I.
CSB 2.33	Addition of alpha-methyltryptamine (AMT) to schedule I.	CSB 2.79	Addition of remimazolam to schedule IV.
CSB 2.34	Addition of 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT).	CSB 2.80	Scheduling of olliceridine.
CSB 2.35	Addition of lisdexamfetamine to schedule II.	CSB 2.81	Addition of brorphine to schedule I.
CSB 2.36	Addition of tramadol to schedule IV.	CSB 2.82	Addition of Serdexmethylphenidate to schedule IV.
CSB 2.37	Rescheduling of hydrocodone combination products.	CSB 2.83	Addition of ten (10) fentanyl-related substances to schedule I.
CSB 2.38	Addition of suvorexant to schedule IV.	CSB 2.84	Addition of alfaxalone to schedule IV.
CSB 2.39	Exclusion of naloxegol.	CSB 2.85	Excluding 6-beta-naltrexol from schedule II.
CSB 2.40	Exclusion of [123I]ioflupane.	CSB 2.86	Addition of fospropofol to schedule IV.
CSB 2.41	Scheduling of beta-hydroxythiofentanyl and butyryl fentanyl.	CSB 2.87	Addition of embutramide to schedule III.
CSB 2.42	Scheduling of furanyl fentanyl.	CSB 2.88	Addition of lacosamide to schedule V.
CSB 2.43	Addition of brivaracetam to schedule V.	CSB 2.89	Addition of perampanel to schedule III.
CSB 2.44	Addition of thiafentanil to schedule II.	CSB 2.90	Transfer of 1-phenylcyclohexylamine and 1-piperidinocyclohexanecarbonitrile, immediate precursors to phencyclidine, also known as PCP, from Schedule I to schedule II.
CSB 2.45	Addition of AB-FUBINACA and ADB-PINACA to schedule I.	CSB 2.91	Addition of 4,4'-Dimethylaminorex to schedule I.
CSB 2.46	Addition of acetyl fentanyl to schedule I.	CSB 2.92	Addition of thirty-eight (38) Anabolic Steroids to schedule III.
CSB 2.47	Addition of AH-7921 to schedule I.	CSB 2.93	Addition of Daridorexant to schedule IV.
CSB 2.48	Addition of eluxadolone to schedule IV.	CSB 2.94	Addition of seven (7) synthetic benzimidazole-opioid substances to schedule I.
		CSB 2.95	Addition of Ganaxolone to schedule V.
		CSB 2.96	Addition of Amineptine to schedule I.
		CSB 2.97	Addition of Zipeprol to schedule I.
		CSB 2.98	Excluding [18F]FP-CIT from schedule II.
		CSB 2.99	Addition of Mesocarb to schedule I.

**CSB 2.01 Addition of methaqualone to schedule II.**

The substance known as methaqualone is hereby added to s. 161.16, Stats., schedule II in sub. (6) which subsection is hereby created.

**Note:** See Chapter 206, Laws of 1981 sections 29 and 31.

**History:** Cr. Register, June, 1973, No. 210, eff. 7-1-73.

**CSB 2.02 Addition of benzphetamine, chlorphentermine, clortermine, mazindol, and phendimetrazine to schedule III.** The substances known as benzphetamine, chlorphentermine, clortermine, mazindol, and phendimetrazine are

hereby added to s. 161.18, Stats., schedule III in sub. (2m) (a), (b), (c), (d) and (e) respectively, which subsections are created to read:

*(2m) Any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system:*

- (a) Benzphetamine
- (b) Chlorphentermine
- (c) Clortermine
- (d) Mazindol

*(e) Phendimetrazine***History:** Cr. Register, October, 1973, No. 214, eff. 11–1–73.**CSB 2.03 Addition of fenfluramine to schedule IV.**

The substance known as fenfluramine is hereby added to s. 161.20, Stats., schedule IV in sub. (2m) (a), which subsection is hereby created to read:

*(2m) Any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system:*

*(a) Fenfluramine:***Note:** See Chapter 206, Laws of 1981 section 47.**History:** Cr. Register, October, 1973, No. 214, eff. 11–1–73.**CSB 2.04 Addition of amobarbital, pentobarbital, and secobarbital to schedule II; retention of certain forms of amobarbital, pentobarbital and secobarbital in schedule III. (1)** Subsection (7) of s. 161.16, Stats., schedule II is hereby created to read as follows:

*(7) Unless excepted under federal regulations or listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances:*

*(a) Amobarbital**(b) Pentobarbital**(c) Secobarbital*

**(2)** Paragraphs (m) and (n) of sub. (3), s. 161.18, Stats., schedule III, are hereby created to read as follows:

*(m) Unless excepted under federal regulations, any compound, mixture, or preparation containing amobarbital, secobarbital, pentobarbital or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule.*

*(n) Unless excepted under federal regulations, any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or any salt of any of these drugs and approved by the federal food and drug administration for marketing only as a suppository.*

**Note:** See Chapter 206, Laws of 1981 sections 30 and 37.**History:** Cr. Register, July, 1974, No. 223, eff. 8–1–74.

**CSB 2.05 Addition of drotebanol to schedule I.** The substance known as drotebanol is hereby added to s. 161.14, Stats., schedule I in sub. (3), par. (hm), which paragraph is created to read:

*(hm) Drotebanol;***History:** Cr. Register, July, 1974, No. 223, eff. 8–1–74.

**CSB 2.06 Addition of pentazocine to schedule III.** Subsection (4m) of s. 161.18, Stats., schedule III is hereby created to read as follows:

*(4m) Pentazocine.***Note:** See Chapter 6, Laws of 1981 sections 2 and 3.**History:** Cr. Register, August, 1974, No. 224, eff. 9–1–74.

**CSB 2.07 Transfer of hydrochloride form of etorphine from schedule I to schedule II. (1)** Subsection (3) (intro.) of s. 161.14, Stats., schedule I is amended to read:

*(3) Unless specifically excepted or listed in another schedule, any of the following opium derivatives, their salts, isomers and salts of isomers whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:*

**(2)** Paragraph (em) of sub. (3), s. 161.16, Stats., schedule II, is hereby created to read:

*(em) Etorphine hydrochloride;***Note:** See Chapter 206, Laws of 1981 sections 6, 20 and 24.**History:** Cr. Register, August, 1974, No. 224, eff. 9–1–74.

**CSB 2.08 Addition of poppy straw to schedule II, addition of pemoline and mebutamate to schedule IV. (1)** Paragraph (d) of sub. (2), s. 161.16, Stats., schedule II is hereby created to read:

*(d) Concentrate of poppy straw (the crude extract of Poppy Straw in either liquid, solid or powder form which contains the phenanthrene alkaloids of the opium poppy).*

**(2)** Paragraph (n) of sub. (2) of s. 161.20, Stats., schedule IV is hereby created to read:

*(n) Mebutamate*

**(3)** Paragraph (b) of sub. (2m) of s. 161.20, Stats., schedule IV is hereby created to read:

*(b) Pemoline:***Note:** See Chapter 206, Laws of 1981 sections 20, 22 and 45.**History:** Cr. Register, February, 1976, No. 242, eff. 3–1–76.

**CSB 2.09 Additions to schedules IV and I. (1)** ADDITION OF BENZODIAZEPINE SUBSTANCES TO SCHEDULE IV. Paragraphs (cm), (cn), (cp), (cr), (em) and (hm) of sub. (2), s. 161.20, Stats., schedule IV are hereby created to read:

*(cm) Chlordiazepoxide**(cn) Clonazepam**(cp) Chlorazepate**(cr) Diazepam**(em) Flurazepam**(hm) Oxazepam*

**(2)** ADDITION OF THE THIOPHENE ANALOG OF PHENCYCLIDINE TO SCHEDULE I. Paragraph (u) of sub. (4), s. 161.14, Stats., schedule I is hereby created to read:

*(u) Thiophene analog of phencyclidine*

**(3)** ADDITION OF MECLOQUALONE TO SCHEDULE I. Subsection (5) and par. (a) of s. 161.14, Stats., schedule I are hereby created to read:

*(5) Depressants. Unless specifically excepted or unless listed in another schedule, any material compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:*

*(a) Mecloqualone*

**(4)** ADDITION OF DIFENOXIN TO SCHEDULE I. Paragraph (hg) of sub. (2), s. 161.14, Stats., schedule I is hereby created to read:

*(hg) Difenoxin*

**(5)** ADDITION OF 2,5 DIMETHOXYAMPHETAMINE, 4-ROMO-2,5 DIMETHOXYAMPHETAMINE AND 4-METHOXYAMPHETAMINE TO SCHEDULE I. Paragraphs (v), (w) and (x) of sub. (4), s. 161.14, Stats., schedule I are hereby created to read:

*(v) 2,5-dimethoxyamphetamine**(w) 4-bromo-2,5-dimethoxyamphetamine**(x) 4-methoxyamphetamine***Note:** See Chapter 206, Laws of 1981 sections 13 and 15.**History:** Cr. Register, April, 1976, No. 244, eff. 5–1–76.

**CSB 2.10 Addition of propiram to schedule I.** Paragraph (wn) of sub. (2), s. 161.14, Stats., schedule I is hereby created to read:

*(wn) Propiram***History:** Cr. Register, August, 1976, No. 248, eff. 9–1–76.

**CSB 2.11 Renumbering and addition to schedule IV of diethylpropion and phentermine.** Paragraph (a) of sub. (2m), s. 161.20, Stats., schedule IV is hereby renumbered to read:

*(b) Fenfluramine*

Paragraph (a) of sub. (2m), s. 161.20, Stats., schedule IV is hereby created to read:

*(a) Diethylpropion*

Paragraph (b) of sub. (2m), s. 161.20, Stats., schedule IV is hereby renumbered to read:

*(c) Pemoline*

Paragraph (d) of sub. (2m), s. 161.20, Stats., schedule IV is hereby created to read:

*(d) Phentermine***History:** Cr. Register, August, 1976, No. 248, eff. 9–1–76.**CSB 2.13 Addition of dextropropoxyphene to schedule IV.** Subsection (4), s. 161.20, Stats., schedule IV is hereby created to read:*(4) Other substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including its salts:**(a) Dextropropoxyphene (Alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane)***Note:** See Chapter 206, Laws of 1981 section 51.**History:** Cr. Register, November, 1977, No. 263, eff. 12–1–77.**CSB 2.14 Addition of prazepam to schedule IV.** Paragraph (km), sub. (2), s. 161.20, Stats., schedule IV is hereby created to read:*(km) Prazepam***History:** Cr. Register, November, 1977, No. 263, eff. 12–1–77.**CSB 2.15 Addition of parahexyl to schedule I; removal of loperamide from schedule V; addition of triazolam to schedule IV.** (1) Paragraph (mn) of sub. (4), s. 161.14, Stats., is created to read:*(mn) Parahexyl*

(2) Paragraph (a) of sub. (3), s. 161.22, Stats., is repealed.

(3) Paragraph (nm) of sub. (2), s. 161.20, Stats., is created to read:

*(nm) Triazolam***History:** Cr. Register, October, 1984, No. 346, eff. 11–1–84.**CSB 2.16 Transfer of sufentanil from schedule I to schedule II.** (1) Section 161.14 (2) (xg), Stats., is repealed.

(2) Section 161.16 (3) (y), Stats., is created to read:

*(y) Sufentanil***History:** Cr. Register, October, 1984, No. 346, eff. 11–1–84.**CSB 2.17 Addition of buprenorphine to schedule V; transfer of methaqualone from schedule II to schedule I; transfer of dronabinol from schedule I to schedule II.**

(2) Paragraph (b) of s. 161.14 (5), Stats., is adopted to read:

*(b) Methaqualone*

(3) Subsection (7) (am) of s. 161.16, Stats., is repealed.

(4) Subsection (10) (a) of s. 161.16, Stats., is created to read:

*(10) Hallucinogenic substances. (a) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. food and drug administration approved drug product. (Other names for dronabinol are (6a R - trans) - 6a, 7, 8, 10a - tetrahydro - 6, 6, 9 - trimethyl - 3 - pentyl - 6H - dibenzo (b, d) pyran - 1 - ol, or (-) - delta - 9 - (trans) - tetrahydrocannabinol.)***History:** Cr. Register, August, 1986, No. 368, eff. 9–1–86; CR 03–056; r. (1) Register January 2004 No. 577, eff. 2–1–04.**CSB 2.18 Addition of 3,4-methylenedioxyamphetamine to schedule I.** Paragraph (am) of s. 161.14 (4), Stats., is created to read:*(am) 3, 4-methylenedioxyamphetamine, commonly known as "MDMA";***History:** Cr. Register, September, 1987, No. 381, eff. 10–1–87.**CSB 2.19 Additions, deletions and transfers to statutory schedules.** (1) Paragraph (b) of s. 161.20 (4), Stats., is created to read:*(b) Not more than 25 milligrams per dosage unit of pentazocine with one or more active, non-narcotic ingredients in recognized therapeutic amounts.*

(2) Paragraph (b) of s. 161.18 (4), Stats., is repealed.

(3) Paragraph (km) of s. 161.20 (2), Stats., is renumbered to read:

*(mg) Prazepam;*(4) Paragraph (hg) of s. 161.20 (2), Stats., is created to read:  
*(hg) Midazolam;*(5) Paragraph (mm) of s. 161.20 (2), Stats., is created to read:  
*(mm) Quazepam;*(6) Paragraph (km) of s. 161.18 (3), Stats., is created to read:  
*(km) Tiletamine and Zolazepam or any salt thereof;*

(7) Paragraph (a) of s. 161.16 (3), Stats., is renumbered to read:

*(am) Alphaprodine;*(8) Paragraph (a) of s. 161.16 (3), Stats., is created to read:  
*(a) Alfentanil;*(9) Paragraph (rg) of s. 161.14 (2), Stats., is created to read:  
*(rg) MPPP 1-methyl-4-phenyl-4-propionoxypiperidine;*(10) Paragraph (vg) of s. 161.14 (2), Stats., is created to read:  
*(vg) (PEPAP) 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine;*

(11) Paragraph (b) of s. 161.16 (10), Stats., is created to read:

*(b) Nabilone (another name for nabilone: (+)-trans-3-(1,1-dimethylheptyl)-6, 6a, 7, 8, 10, 10a-hexahydro-1-hydroxy-6, 6-dimethyl-9H-dibenzo [b,d] pyran-9-one).*

(12) Subsection (2) of s. 161.14, Stats., is amended to read:

*(2) Opiates. Unless specifically excepted under federal regulations or unless listed in another schedule, any of the following opiates, or their isomers, esters, ethers, salts, salts of isomers, esters of ethers, if isomers, esters, ethers, salts or salts of isomers exist within the specified chemical designation (for purposes of par. (tg) only, the term isomer includes the optical and geometric isomers):*

(13) Paragraph (a) of s. 161.14 (2), Stats., is renumbered to read:

*(ag) Acetylmethadol;*

(14) Paragraph (a) of s. 161.14 (2), Stats., is created to read:

*(a) Acetyl-alpha-methylfentanyl (N-(1-(1-methyl-2-phenethyl)-4-piperidinyl)-N-phenylacetamide);*(15) Paragraph (cg) of s. 161.14 (2), Stats., is created to read:  
*(cg) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);*(16) Paragraph (dg) of s. 161.14 (2), Stats., is created to read:  
*(dg) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide);*(17) Paragraph (rj) of s. 161.14 (2), Stats., is created to read:  
*(rj) 3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);*(18) Paragraph (tg) of s. 161.14 (2), Stats., is created to read:  
*(tg) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]propanamide);*(19) Paragraph (xm) of s. 161.14 (2), Stats., is created to read:  
*(xm) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]propanamide);***History:** Cr. Register, February, 1988, No. 386, eff. 3–1–88.**CSB 2.20 Addition of beta-hydroxy-3-methylfentanyl to schedule I.** Paragraph (er) of s. 161.14 (2), Stats., is created to read:*(er) Beta-hydroxy-3-methylfentanyl.***History:** Cr. Register, July, 1989, No. 403, eff. 8–1–89.**CSB 2.21 Additions, deletions, corrections, transfers, and amendments to drug schedules.** (1) Subsection (1) of s. 161.14, Stats., is amended to read:*(1) Included substances. Unless specifically excepted by state or federal law or regulation or more specifically included in another schedule, the following controlled substances are listed in schedule I.*

(2) Paragraph (a) of s. 161.14 (2), Stats., is amended to read:



(a) *Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenylethyl)-4-piperidinyl]-N-phenylacetamide)*;

(3) Paragraph (er) of s. 161.14 (2), Stats., is amended to read:  
(er) *Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide)*;

(4) Paragraph (rg) of s. 161.14 (2), Stats., is amended to read:  
(rg) *MPPP (1-methyl-4-phenyl-4-propionoxypiperidine)*;

(5) Paragraph (qs) of s. 161.14 (2), Stats., is amended to read:  
(qs) *3-methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidinyl]-N-phenylpropanamide)*;

(6) Paragraph (tg) of s. 161.14 (2), Stats., is amended to read:  
(tg) *Para-fluorofentanyl (N-[1-(2-phenylethyl)-4-piperidinyl]-N-(4-fluorophenyl)propanamide)*;

(7) Paragraph (vg) of s. 161.14 (2), Stats., is amended to read:  
(vg) *PEPAP (1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine)*;

(8) Paragraph (xm) of s. 161.14 (2), Stats., is amended to read:  
(xm) *Thiofentanyl (N-[1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide)*;

(9) Paragraph (cd) of s. 161.14 (2), Stats., is created to read:  
(cd) *Alpha-methylfentanyl (N-[1-(1-methyl-2-phenylethyl)-4-piperidinyl]-N-phenylpropanamide)*;

(10) Paragraph (e) of s. 161.14 (3), Stats., is amended to read:  
(e) *Codeine-N-oxide*;

(11) Paragraph (j) of s. 161.14 (3), Stats., is amended to read:  
(j) *Etorphine, except its hydrochloride salts*;

(12) Paragraph (s) of s. 161.14 (3), Stats., is amended to read:  
(s) *Morphine-N-oxide*;

(13) Paragraph (a) of s. 161.14 (4), Stats., is amended to read:  
(a) *3,4-methylenedioxyamphetamine, commonly known as "MDA"*;

(14) Paragraph (b) of s. 161.14 (4), Stats., is amended to read:  
(b) *5-methoxy-3,4-methylenedioxyamphetamine*;

(15) Paragraph (c) of s. 161.14 (4), Stats., is amended to read:  
(c) *3,4,5-trimethoxyamphetamine*;

(16) Paragraph (ag) of s. 161.14 (4), Stats., is created to read:  
(ag) *3,4-methylenedioxyethylamphetamine, commonly known as "MDE"*;

(17) Paragraph (ar) of s. 161.14 (4), Stats., is created to read:  
(ar) *N-hydroxy-3,4-methylenedioxyamphetamine*;

(18) Paragraph (u) of s. 161.14 (4), Stats., is amended to read:  
(u) *1-[1-(2-thienyl)cyclohexyl]piperidine, which is the thiophene analog of phencyclidine*;

(19) Paragraph (ud) of s. 161.14 (4), Stats., is created to read:  
(ud) *1-[1-(2-thienyl)cyclohexyl]pyrrolidine, which is the thiophene pyrrolidine analog of phencyclidine*;

(20) Paragraph (ur) of s. 161.14 (4), Stats., is amended to read:  
(ur) *1-(1-phenylcyclohexyl)pyrrolidine, which is the pyrrolidine analog of phencyclidine*;

(21) Paragraph (d) of s. 161.14 (7), Stats., is created to read:  
(d) *4-methylaminorex, including its salts and salts of isomers*;

(22) Paragraph (e) of s. 161.14 (7), Stats., is created to read:  
(e) *N,N-dimethylamphetamine, including its salts and salts of isomers*.

(23) Paragraph (L) of s. 161.14 (7), Stats., is created to read:  
(L) *methcathinone, including its salts and salts of isomers*.

(24) Subdivision 4m of s. 161.16 (2) (a), Stats., is created to read:  
4m. *Dihydrocodeine*;

(25) Paragraph (d) of s. 161.16 (3), Stats., is repealed.

(26) Paragraph (am) of s. 161.16 (7), Stats., is created to read:  
(am) *Glutethimide*;

(27) Subsection (9) of s. 161.16, Stats., is repealed.

(28) Subsection (20m) of s. 161.01, Stats., is created to read:  
(20m) (a) *"Anabolic steroid" means any drug or hormonal substance, chemically or pharmacologically related to testosterone (except estrogens, progestin, and corticosteroids), that promotes muscle growth. The term includes all of the substances listed in s. 161.18 (7), and their esters, isomers, esters of isomers, salts and salts of esters, isomers and esters of isomers, that are theoretically possible under the specific chemical designation, and if such esters, isomers, esters of isomers, salts and salts of esters, isomers and esters of isomers promote muscle growth.*

(b) *Except as provided in par. (c), the term does not include an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the United States secretary of health and human services for such administration.*

(c) *If a person prescribes, dispenses or distributes such steroid for human use, such person shall be considered to have prescribed, dispensed or distributed an anabolic steroid within the meaning of par. (a).*

(29) Subsection (7) of s. 161.18, Stats., is created to read:

(7) *Anabolic steroids. Any material, compound, mixture, or preparation containing any quantity of the following anabolic steroids, including any of their esters, isomers, esters of isomers, salts and salts of esters, isomers and esters of isomers, whenever those esters, isomers, esters of isomers, salts and salts [of] esters, isomers and esters of isomers exist within the specific chemical designation:*

(a) *Boldenone*;

(b) *4-chlorotestosterone, which is also called clostebol*;

(c) *Dehydrochloromethyltestosterone*;

(d) *4-dihydrotestosterone, which is also called stanolone*;

(e) *Drostanolone*;

(f) *Ethylestrenol*;

(g) *Fluoxymesterone*;

(h) *Formebolone, which is also called fromebolone*;

(i) *Mesterolone*;

(j) *Methandienone, which is also called methandrostenolone*;

(k) *Methandriol*;

(l) *Methenolone*;

(m) *Methyltestosterone*;

(n) *Mibolerone*;

(o) *Nandrolone*;

(p) *Norethandrolone*;

(q) *Oxandrolone*;

(r) *Oxymesterone*;

(s) *Oxymetholone*;

(t) *Stanozolol*;

(u) *Testolactone*;

(v) *Testosterone*;

(w) *Trenbolone*.

(30) Paragraphs (ar), (av), (cd), (cg), (co), (cq), (cu), (ed), (eg), (ej), (ep), (es), (eu), (ey), (hh), (hj), (hk), (hr), (md) and (ng) of s. 161.20 (2), Stats., are created to read:

(ar) *Bromazepam*;

(av) *Camazepam*;

(cd) *Clobazam*;

(cg) *Clotiazepam*;

(co) *Cloxazolam*;

(cq) *Delorazepam*;

(cu) *Estazolam*;

(ed) *Ethyl loflazepate*;

(eg) *Fludiazepam*;

(ej) *Flunitrazepam*;

(ep) *Haloxazolam*;

(es) *Loprazolam*;

(eu) Lormetazepam;  
 (ey) Medazepam;  
 (hh) Nimetazepam;  
 (hj) Nitrazepam;  
 (hk) Nordiazepam;  
 (hr) Oxazolam;  
 (md) Pinazepam;  
 (ng) Tetraxepam.

(31) Paragraph (eq) of s. 161.20 (2), Stats., is repealed and recreated to read:

(eq) Ketazolam

(32) Paragraph (o) of s. 161.20 (2), Stats., is repealed.

(33) Paragraphs (ag), (ar) and (bm) of s. 161.20 (2m), Stats., are created to read:

(ag) *N,N-dimethyl-1,2-diphenylethylamine*, commonly known as “SPA”;

(ar) *Fencamfamine*;

(bm) *Mazindol*;

(34) Paragraph (b) of s. 161.20 (4), Stats., is repealed and recreated to read:

(b) *Pentazocine, including its isomers and salts of isomers.*

History: Cr. Register, November, 1992, No 443, eff. 12–1–92.

**CSB 2.22 Additions to drug schedules.** (1) Paragraph (b) of s. 161.14 (2), Stats., is amended to read:

(b) *Alphacetylmethadol (except Levo–alphacetylmethadol (LAAM))*

(2) Paragraph (cm) of s. 161.14 (4), Stats., is created to read:  
 (cm) *Alpha–ethyltryptamine, its optical isomers, salts and salts of isomers;*

(3) Paragraph (bm) of s. 161.14 (4), Stats., is created to read:  
 (bm) *2,5–dimethoxy–4–ethylamphetamine, commonly known as DOET;*

(4) Paragraph (am) of s. 161.14 (7), Stats., is created to read:  
 (am) *Aminorex, its salts, optical isomers, and salts of optical isomers;*

(5) Paragraph (ag) of s. 161.14 (7), Stats., is created to read:  
 (ag) *Cathinone;*

(6) Paragraph (gm) of s. 161.16 (3), Stats., is created to read:  
 (gm) *Levo–alphacetylmethadol (LAAM)*

History: Cr. Register, August, 1994, No. 464, eff. 9–1–94.

**CSB 2.23 Additions and amendments to drug schedules.** (1) Paragraph (wg) of s. 161.14 (4), Stats., is created to read:

(wg) *4–bromo–2,5–dimethoxyphenethylamine;*

(2) Subsection (7) (intro.) of s. 161.17, Stats., is amended to read:

(7) *Anabolic steroids. Unless specifically excepted under federal regulations, any compound, material, compound, mixture or preparation containing any quantity of the following anabolic steroids, including any of their esters, isomers, esters of isomers, salts and salts of esters, isomers and esters of isomers, whenever those esters, isomers, esters of isomers, salts and salts [of] esters, isomers and esters of isomers exist within the specific chemical designation:*

(3) Paragraph (3) (c), of s. 161.18, Stats., is repealed.

History: Cr. Register, November, 1994, No. 467, eff. 12–1–94.

**CSB 2.24 Addition of butorphanol to schedule IV.** (1) Paragraph (c) of s. 961.20 (4), Stats., is created to read:

(c) *Butorphanol, including any of its isomers and salts of isomers.*

History: Cr. Register, November, 1998, No. 515, eff. 12–1–98.

**CSB 2.25 Addition of remifentanyl to schedule II; transfer of dronabinol from schedule II to schedule III;**

**addition of fenproporex, modafinil, sibutramine, zaleplon and zolpidem to schedule IV; spelling correction of carfentanil.** (1) Section 961.16 (3) (cm), Stats., is amended to read:

(cm) *Carfentanil;*

(2) Section 961.16 (3) (xm), Stats., is created to read:

(xm) *Remifentanil;*

(3) Section 961.16 (10) (a), Stats., is repealed.

(4) Section 961.18 (4m), Stats., is created to read:

(4m) *Hallucinogenic substances. Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. food and drug administration approved drug product. (Other names for dronabinol are (6aR–trans)–6a, 7, 8, 10a–tetrahydro–6, 6. 9–trimethyl–3–pentyl–6H–dibenzo(b, d)pyran–1–ol, and (–)–delta–9–(trans)–tetrahydrocannabinol.)*

(5) Section 961.20 (2) (o) and (p), Stats., is created to read:

(o) *Zaleplon.*

(p) *Zolpidem.*

(6) Section 961.20 (2m) (at), (bu) and (f), Stats., is created to read:

(at) *Fenproporex.*

(bu) *Modafinil.*

(f) *Sibutramine.*

History: Cr. Register, July, 2000, No. 535, eff. 8–1–00.

**CSB 2.26 Addition of dihydroetorphine to schedule II.** (1) Section 961.16 (2) (a) 4r., Stats., is created to read:

4r. *Dihydroetorphine.*

History: CR 01–071: Cr. Register November 2001 No. 551, eff. 12–1–01.

**CSB 2.28 Addition of dichloralphenazone to schedule IV.** (1) Section 961.20 (2) (cs), Stats., is created to read:

Section 961.20 (2) (cs) *Dichloralphenazone;*

History: CR 02–025: Cr. Register October 2002 No. 562, eff. 11–1–02.

**CSB 2.29 Transfer of buprenorphine from schedule V to schedule III.** (1) Section 961.18 (5m), Stats., is created to read:

Section 961.18 (5m) *NARCOTIC DRUGS NOT LIMITED BY QUANTITY. Any material, compound, mixture, or preparation containing any of the following narcotic drugs, including any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation:*

(a) *Buprenorphine*

History: CR 03–056: cr. Register January 2004 No. 577, eff. 2–1–04.

**CSB 2.30 Addition of gamma–hydroxybutyric acid to schedule III.** (1) Section 961.18 (3) (o), Stats., is created to read:

Section 961.18 (3) (o) *Any drug product containing gamma–hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the federal food, drug and cosmetic act:*

1. *Gamma–hydroxybutyric acid.*

History: CR 03–057: cr. Register January 2004 No. 577, eff. 2–1–04.

**CSB 2.31 Addition of 2,5 dimethoxy–4–(n)– propylthiophenethylamine (2C–T–7) to schedule I.** (1) Section 961.14 (4) (wh), Stats., is created to read:

Section 961.14 (4) (wh) *2,5 dimethoxy–4–(n)– propylthiophenethylamine, commonly known as “2C–T–7”;*

History: CR 06–058: cr. Register April 2007 No. 616, eff. 5–1–07.

**CSB 2.32 Addition of N– benzylpiperazine (BZP) to schedule I.** (1) Section 961.14 (7) (q), Stats., is created to read:  
 Section 961.14 (7) (q) *N– benzylpiperazine, commonly known as “BZP.”*

History: CR 06–058: cr. Register April 2007 No. 616, eff. 5–1–07.

**CSB 2.33 Addition of alpha-methyltryptamine (AMT) to schedule I.** (1) Section 961.14 (4) (wi), Stats., is created to read:

Section 961.14 (4) (wi) *Alpha-methyltryptamine, commonly known as “AMT”*;

**History:** CR 06–059: cr. Register April 2007 No. 616, eff. 5–1–07.

**CSB 2.34 Addition of 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT).** (1) Section 961.14 (4) (wj), Stats., is created to read:

Section 961.14 (4) (wj) *5-methoxy-N, N-diisopropyltryptamine, commonly known as “5-MeO-DIPT”*;

**History:** CR 06–059: cr. Register April 2007 No. 616, eff. 5–1–07.

**CSB 2.35 Addition of lisdexamfetamine to schedule II.** (1) Section 961.16 (5) (e), Stats., is created to read:

Section 961.16 (5) (e) *Lisdexamfetamine, commonly known as “Vyvanse TM.”*

**History:** CR 10–112: cr. Register April 2011 No. 664, eff. 5–1–11.

**CSB 2.36 Addition of tramadol to schedule IV.** Section 961.20 (4) (e), Stats., is created to read:

Section 961.20 (4) (e) *Tramadol, including any of its isomers and salts of isomers.*

**History:** cr. Affirmative action order under s. 968.11 (4), Stats., Register August 2014 No. 704, eff. 9–1–14; CR 15–008: cr. Register October 2015 No. 718, eff. 11–1–15.

**CSB 2.37 Rescheduling of hydrocodone combination products.** Sections 961.18 (5) (c) and (d), Stats., are repealed.

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2014 No. 706, eff. 11–1–14; CR 15–007: cr. Register October 2015 No. 718, eff. 11–1–15.

**CSB 2.38 Addition of suvorexant to schedule IV.** Section 961.20 (2) (mr), Stats., is created to read:

Section 961.20 (2) (mr) *Suvorexant.*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2014 No. 706, eff. 11–1–14; CR 15–009: cr. Register October 2015 No. 718, eff. 11–1–15.

**CSB 2.39 Exclusion of naloxegol.** Section 961.16 (2) (a) (intro.), Stats., is amended to read:

961.16 (2) (a) (intro) *Opium and substances derived from opium, and any salt, compound, derivative or preparation of opium or substances derived from opium. Apomorphine, dextrorphan, nalbuphine, butorphanol, nalmefene, naloxegol, naloxone and naltrexone and their respective salts and the isoquinoline alkaloids of opium and their respective salts are excluded from this paragraph. The following substances, and any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register April 2015 No. 711B, eff. 4–1–15; CR 15–068: cr. Register August 2016 No. 728, eff. 9–1–16.

**CSB 2.40 Exclusion of [<sup>123</sup>I]ioflupane.** Section 961.16 (2) (b), Stats., is amended to read:

(b) *Coca leaves and any salt, compound, derivative or preparation of coca leaves. Decocainized coca leaves or extractions which do not contain cocaine or ecgonine are excluded from this paragraph. [<sup>123</sup>I]ioflupane is excluded from this paragraph. The following substances and any of their salts, esters, isomers and salts of esters and isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2015 No. 718A3, eff. 10–19–15; correction made under s. 35.17, Stats., Register October 2015 No. 718; CR 16–060: cr. Register May 2017 No. 737, eff. 6–1–17.

**CSB 2.41 Scheduling of beta-hydroxythiofentanyl and butyryl fentanyl.** Sections 961.14 (2) (eu) and (ey) are created to read:

961.14 (2) (eu) *Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide)*

(ey) *Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide)*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register August 2016 No. 728, eff. 7–18–16; CR 16–081: cr. Register July 2017 No. 739, eff. 8–1–17.

**CSB 2.42 Scheduling of furanyl fentanyl.** Section 961.14 (2) (ne) is created to read:

961.14 (2) (ne) *Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide).*

**History:** EmR1626: emerg. cr., eff. 9–1–16; CR 16–059: cr. Register May 2017 No. 737, eff. 6–1–17.

**CSB 2.43 Addition of brivaracetam to schedule V.** Section 961.22 (6), Stats., is created to read:

961.22 (6) *BRIVARACETAM. Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide), including its salts, isomers or salts of isomers.*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register September 2016 No. 729, eff. 9–26–16; CR 17–009: cr. Register July 2017 No. 739, eff. 8–1–17.

**CSB 2.44 Addition of thiafentanil to schedule II.** Section 961.16 (3) (zx), Stats., is created to read:

961.16 (3) (zx) *Thiafentanil.*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2016 No. 730, eff. 10–3–16; CR 17–007: cr. Register July 2017 No. 739, eff. 8–1–17.

**CSB 2.45 Addition of AB-FUBINACA and ADB-PINACA to schedule I.** Section 961.14 (4) (tb) 32. and 33., Stats., is created to read:

961.14 (4) (tb) 32. *N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, commonly known as AB-FUBINACA.*

33. *N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, commonly known as ADB-PINACA.*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2016 No. 730, eff. 10–10–16; CR 17–008: cr. Register July 2017 No. 739, eff. 8–1–17.

**CSB 2.46 Addition of acetyl fentanyl to schedule I.** Section 961.14 (2) (ae), Stats., is created to read:

961.14 (2) (ae) *Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide).*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2016 No. 731, eff. 11–21–16; CR 17–021: cr. Register November 2017 No. 743, eff. 12–1–17.

**CSB 2.47 Addition of AH-7921 to schedule I.** Section 961.14 (2) (aj), Stats., is created to read:

961.14 (2) (aj) *AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide).*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2016 No. 731, eff. 11–21–16; CR 17–023: cr. Register November 2017 No. 743, eff. 12–1–17.

**CSB 2.48 Addition of eluxadoline to schedule IV.** Section 961.20 (4) (cm), Stats., is created to read:

961.20 (4) (cm) *Eluxadoline, including any of its isomers, and salts of isomers.*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2016 No. 731, eff. 11–21–16; CR 17–022: cr. Register November 2017 No. 743, eff. 12–1–17.

**CSB 2.49 Addition of U-47700 to schedule I.** Section 961.14 (2) (z), Stats., is created to read:

961.14 (2) (z) *U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide).*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register December 2016 No. 732, eff. 12–19–16; CR 17–020: cr. Register November 2017 No. 743, eff. 12–1–17.



**CSB 2.50 Addition of AB-CHMINACA, AB-PINACA and THJ-2201 to schedule I.** Section 961.14 (4) (tb) 34., 35., and 36., Stats., are created to read:

961.14 (4) (tb) 34. *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1*H*-indazole-3-carboxamide, commonly known as AB-CHMINACA.

35. *N*-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1*H*-indazole-3-carboxamide, commonly known as AB-PINACA).

36. [1-(5-fluoropentyl)-1*H*-indazol-3-yl](naphthalen-1-yl)methanone, commonly known as THJ-2201.

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register April 2017 No. 736, eff. 3-27-17; correction in (intro.) made under s. 35.17, Stats., Register April 2017 No. 736; CR 17-085; cr. Register October 2018 No. 754, eff. 11-1-18; correction in (intro.) made under s. 35.17, Stats., Register October 2018 No. 754.

**CSB 2.51 Addition of MAB-CHMINACA to schedule I.** Section 961.14 (4) (tb) 37., Stats., is created to read:

961.14 (4) (tb) 37. *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1*H*-indazole-3-carboxamide, commonly known as MAB-CHMINACA or ADB-CHMINACA.

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register April 2017 No. 736, eff. 3-27-17; CR 17-086; cr. Register October 2018 No. 754, eff. 11-1-18.

**CSB 2.52 Addition of 4-MePPP and a-PBP to schedule I.** Section 961.14 (7) (L) 32. and 33., Stats., is created to read:

961.14 (7) (L) 32. 4-methyl- $\alpha$ -pyrrolidinopropiophenone, commonly known as 4-MePPP.

33.  $\alpha$ -pyrrolidinobutiophenone, commonly known as a-PBP.

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register April 2017 No. 736, eff. 4-10-17; CR 17-087; cr. Register October 2018 No. 754, eff. 11-1-18.

**CSB 2.53 Scheduling of acryl fentanyl.** Section 961.14 (2) (ai), Stats., is created to read:

961.14 (2) (ai) Acryl fentanyl (*N*-phenyl-*N*-[1-(2-phenylethyl)piperidin-4-yl]-2-propenamamide);

**Note:** Section 961.14 (2) (ai), Stats., was renumbered to s. 961.14 (2) (nd) 3. by 2017 Wis. Act 60.

**History:** EmR1710; emerg. cr. eff. 5-2-17; CR 17-040; cr. Register November 2017 No. 743, eff. 12-1-17; correction made under s. 35.17, Stats., Register November 2017 No. 743.

**CSB 2.54 Addition of oral solutions containing dronabinol to schedule II.** Section 961.16 (10), Stats., is created to read:

961.16 (10) (a) Dronabinol [(*-*)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)] in an oral solution in a drug product approved by the U.S. food and drug administration.

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register May 2017 No. 737, eff. 5-15-17; CR 18-055; cr. Register June 2019 No. 762, eff. 7-1-19.

**CSB 2.55 Addition of 5F-ADB, 5F-AMB, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA to schedule I.** Section 961.14 (4) (tb) 38., 39., 40., 41., and 42., Stats., is created to read:

961.14 (4) (tb) 38. Methyl 2-(1-(5-fluoropentyl)-1*H*-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-ADB.

39. Methyl 2-(1-(5-fluoropentyl)-1*H*-indazole-3-carboxamido)-3-methylbutanoate, commonly known as 5F-AMB.

40. *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1*H*-indazole-3-carboxamide, commonly known as ADB-FUBINACA.

41. Methyl 2-(1-(cyclohexylmethyl)-1*H*-indole-3-carboxamido)-3,3-dimethylbutanoate commonly known as MDMB-CHMICA.

42. Methyl 2-(1-(4-fluorobenzyl)-1*H*-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as MDMB-FUBINACA.

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register May 2017 No. 737, eff. 5-15-17; CR 17-088; cr. Register October 2018 No. 754, eff. 11-1-18.

**CSB 2.56 Addition of 4-fluoroisobutyryl fentanyl to schedule I.** Section 961.14 (2) (nd) 10t., Stats., is created to read:

961.14 (2) (nd) 10t. 4-fluoroisobutyryl fentanyl (*N*-(4-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)isobutyramide);

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register June 2017 No. 738, eff. 6-12-17; CR 17-089; cr. Register October 2018 No. 754, eff. 11-1-18.

**CSB 2.57 Scheduling of cyclopropyl fentanyl.** Section 961.14 (2) (nd) 10d., Stats., is created to read:

961.14 (2) (nd) 10d. Cyclopropyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylcyclopropanecarboxamide);

**History:** EmR 1716; emerg. cr. eff. 9-8-17; CR 17-0785; cr. Register July 2018 No. 751, eff. 8-1-18; corrections made under s. 35.17, Stats., Register July 2018 No. 751.

**CSB 2.58 Exclusion of naldemedine.** Section 961.16 (2) (a) (intro), Stats., is amended to read:

961.16 (2) (a) (intro) Opium and substances derived from opium, and any salt, compound, derivative or preparation of opium or substances derived from opium. Apomorphine, dextrorphan, nalbuphine, butorphanol, naldemedine, nalmefene, naloxegol, naloxone and naltrexone and their respective salts and the isoquinoline alkaloids of opium and their respective salts are excluded from this paragraph. The following substances, and any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2017 No. 743, eff. 11-20-17; CR 18-024; cr. Register June 2019 No. 762, eff. 7-1-19.

**CSB 2.59 Addition of ortho-fluorofentanyl to schedule I.** Section 961.14 (2) (nd) 16m., Stats., is created to read:

961.14 (2) (nd) 16m. Ortho-fluorofentanyl (*N*-(2-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)propionamide);

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register December 2017 No. 744, eff. 12-4-17; correction made under s. 35.17, Stats., Register December 2017 No. 744; CR 18-023; cr. Register June 2019 No. 762, eff. 7-1-19.

**CSB 2.60 Addition of FUB-AMB to schedule I.** Section 961.14 (4) (tb) 43., Stats., is created to read:

961.14 (4) (tb) 43. methyl 2-(1-(4-fluorobenzyl)-1*H*-indazole-3-carboxamido)-3-methylbutanoate, commonly known as FUB-AMB, MMB-FUBINACA or AMB-FUBINACA.

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register December 2017 No. 744, eff. 12-11-17; correction made under s. 35.17, Stats., Register December 2017 No. 744; CR 18-022; cr. Register June 2019 No. 762, eff. 7-1-19.

**CSB 2.61 Addition of MT-45 to schedule I.** Section 961.14 (2) (rk), Stats., is created to read:

961.14 (2) (rk) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register January 2018 No. 745, eff. 1-22-18; correction made under s. 35.17, Stats., Register January 2018 No. 745; CR 18-069; cr. Register June 2019 No. 762, eff. 7-1-19.

**CSB 2.62 Addition of para-chloroisobutyryl fentanyl to schedule I.** Section 961.14 (2) (nd) 16s., Stats., is created to read:

961.14 (2) (nd) 16s. Para-chloroisobutyryl fentanyl (*N*-(4-chlorophenyl)-*N*-(1-phenethylpiperidin-4-yl)isobutyramide);

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2018 No. 747, eff. 3-12-18; CR 18-070; cr. Register June 2019 No. 762, eff. 7-1-19.

**CSB 2.63 Addition of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA to schedule I.** Section 961.14 (4) (tb) 44., 45., 46., 47., and 48., Stats., are created to read:

961.14 (4) (tb) 44. *Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, commonly known as NM2201.*

45. *N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide, commonly known as 5F-AB-PINACA.*

46. *1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, commonly known as 4-CN-CUMYL-BUTINACA.*

47. *Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate, commonly known as MMB-CHMICA.*

48. *1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide, commonly known as 5F-CUMYL-P7AICA.*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2018 No. 747, eff. 3–12–18; cr. Affirmative action order under s. 961.11 (4), Stats., Register August 2018 No. 752, eff. 8–13–18; correction made under s. 35.17, Stats., Register August 2018 No. 752; CR 19–010: cr. Register June 2020 No. 774, eff. 7–1–20; correction made under s. 35.17, Stats., Register June 2021 No. 786.

**CSB 2.64 Addition of N-Ethylpentylone to schedule I.** Section 961.14 (7) (L) 34., Stats., is created to read:

961.14 (7) (L) 34. *N-Ethylpentylone, commonly known as ephylone.*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2018 No. 754, eff. 10–8–18; CR 19–011: cr. Register June 2020 No. 774, eff. 7–1–20.

**CSB 2.65 Addition of approved cannabidiol drugs to schedule V.** Section 961.22 (7), Stats., is created to read:

961.22 (7) *Approved cannabidiol drugs. A drug product in finished dosage formulation that has been approved by the United States food and drug administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.*

**History:** cr. Affirmative action order under s. 961.11 (4g), Stats., Register October 2018 No. 754, eff. 10–15–18; CR 19–012: cr. Register June 2020 No. 774, eff. 7–1–20.

**CSB 2.66 Addition of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 to schedule I.** Section 961.14 (4) (tb), 49., 50., 51., 52., and 53., Stats., are created to read:

961.14 (4) (tb) 49. *Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-EDMB-PINACA.*

50. *Methyl 2-(1-(5-fluoropentyl)-1-indole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-MDMB-PICA.*

51. *N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, commonly known as FUB-AKB48, FUB-APINACA or AKB48 N-(4-FLUOROBENZYL).*

52. *1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, commonly known as 5F-CUMYL-PINACA or SGT-25.*

53. *(1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone, commonly known as FUB-144.*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2019 No. 759, eff. 3–11–19; CR 20–048: cr. Register June 2021 No. 786, eff. 7–1–21.

**CSB 2.67 Addition of Brexanolone and Solriamfetol to schedule IV.** Section 961.20 (2) (ap) and (2m) (g), Stats., are created to read:

961.20 (2) (ap) *Brexanolone;*

(2m) (g) *Solriamfetol.*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register July 2019 No. 763, eff. 7–22–19; CR 20–049: cr. Register June 2021 No. 786, eff. 7–1–21; correction in (2) (ap) made under s. 35.17, Stats., Register June 2021 No. 785.

**CSB 2.68 Addition of N-Ethylhexedrone, a-PHP, 4-MEAP, MPHP, PV8 and 4-chloro-a-PVP to schedule I.** Section 961.14 (7) (L) 35. to 40., Stats., is created to read:

961.14 (7) (L) 35. *N-Ethylhexedrone.*

36. *Alpha-pyrrolidinohexanophenone, commonly known as a-PHP.*

37. *4-methyl-alpha-ethylainopentiophenone, commonly known as 4-MEAP.*

38. *4'-methyl-alpha-pyrrolidinohexiophenone, commonly known as MPHP.*

39. *Alpha-pyrrolidinoheptaphenone, commonly known as PV8.*

40. *4'-chloro-alpha-pyrrolidinovalerophenone, commonly known as 4-chloro-a-PVP.*

**History:** cr. Affirmative action order under s. 961.11 (4g), Stats., Register August 2019 No. 764, eff. 8–19–19; CR 20–050: cr. Register June 2021 No. 786, eff. 7–1–21.

**CSB 2.69 Addition of Noroxymorphone to schedule II.** Section 961.16 (2) (a) 10m., Stats., is created to read:

961.16 (2) (a) 10m. *Noroxymorphone.*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2019 No. 767, eff. 11–11–19; CR 20–051: cr. Register June 2021 No. 786, eff. 7–1–21.

**CSB 2.70 Scheduling 4F-MDMB-BINACA and MMB-FUBICA.** Section 961.14 (4) (tb) 38m. and 43m., Stats., are created to read:

961.14 (4) (tb) 38m. *Methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 4F-MDMB-BINACA or 4F-MDMB-BUTINACA.*

43m. *Methyl 2-(1-(4-fluorobenzyl)-1H-indole-3-carboxamido)-3-methylbutanoate, commonly known as MMB-FUBICA or AMB-FUBICA.*

**History:** EmR2017: emerg. cr., eff. 6–26–20; CR 20–022: cr. Register May 2021 No. 785, eff. 6–1–21.

**CSB 2.71 Addition of lasmiditan to schedule V.** Section 961.22 (8), Stats., is created to read:

961.22 (8). *Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl)-benzamide].*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2020 No. 771, eff. 3–23–20; CR 20–058: cr. Register July 2021 No. 787, eff. 8–1–21.

**CSB 2.72 Scheduling of isotonitazene and 1P-LSD.** Section 961.14 (2) (pe) and (4) (jm), Stats., are created to read:

961.14 (2) (pe) *Isotonitazene;*

961.14 (4) (jm) *1-propionyl-lysergic acid diethylamide, commonly known as 1P-LSD;*

**History:** EmR2013: emerg. cr., eff. 6–5–20; CR 20–023: cr. Register May 2021 No. 785, eff. 6–1–21; correction made under s. 35.17, Stats., Register May 2021 No. 785.

**CSB 2.73 Addition of cenobamate to schedule V.** Section 961.22 (9), Stats., is created to read:

961.22 (9) *CENOBAMATE Cenobamate [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate; 2H-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester]*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register May 2020 No. 773, eff. 5–18–20; CR 20–075: cr. Register July 2021 No. 787, eff. 8–1–21.

**CSB 2.74 Addition of Lemborexant to schedule IV.** Section 961.20 (2) (eqm), Stats., is created to read:



*961.20 (2) (eqm) Lemborexant.*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2020 No. 771, eff. 5–18–20; CR 20–076: cr. Register July 2021 No. 787, eff. 8–1–21; correction made under s. 35.17, Stats., Register July 2021 No. 787.

**CSB 2.75 Exclusion of approved cannabidiol drugs from schedule I.** (1) Section 961.14 (4) (t) 4., Stats., is created to read:

*961.14 (4) (t) 4. A drug product in finished dosage formulation that has been approved by the United States food and drug administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.*

(2) Section 961.22 (7) is repealed.

**History:** cr. Affirmative action order under s. 961.11 (4g), Stats., Register June 2020 No. 774, eff. 6–29–20; CR 20–077: cr. Register July 2021 No. 787, eff. 8–1–21.

**CSB 2.76 Addition of norfentanyl to schedule II.**

(1) Section 961.16 (8) (b), Stats., is renumbered 961.16 (8) (b) (intro.) and amended to read:

*961.16 (8) (b) An immediate precursor to fentanyl, including all of the following:*

1. *4-anilino-N-phenethyl-4-piperidine, commonly known as ANPP.*

(2) Section 961.16 (8) (b) 2., Stats. is created to read:

2. *N-phenyl-N-(piperidin-4-yl)propionamide, commonly known as norfentanyl.*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register June 2020 No. 774, eff. 6–29–20; CR 20–078: cr. Register July 2021 No. 787, eff. 8–1–21.

**CSB 2.77 Scheduling of flualprazolam.** Section 961.20 (2) (ef), Stats., is created to read:

*961.20 (2) (ef) Flualprazolam;*

**History:** EmR1037: emerg. cr., eff. 10–27–20; CR 20–078: cr. Register July 2021 No. 787, eff. 8–1–21; correction made under s. 35.17, Stats., Register July 2021 No. 787.

**CSB 2.78 Addition of crotonyl fentanyl to schedule I.** Section 961.14 (2) (nd) 9m., Stats., is created to read:

*961.14 (2) (nd) 9m. Crotonyl Fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide);*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2020 No. 779, eff. 11–23–20.

**CSB 2.79 Addition of remimazolam to schedule IV.** Section 961.20 (2) (mo), Stats., is created to read:

*961.20 (2) (mo) Remimazolam;*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2020 No. 779, eff. 11–23–20.

**CSB 2.80 Scheduling of oliceridine.** Section 961.16 (3) (ta), Stats., is created to read:

*961.16 (3) (ta) Oliceridine;*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register December 2020 No. 780, eff. 12–14–20; CR 21–098: cr. Register August 2022 No. 800, eff. 9–1–22.

**CSB 2.81 Addition of bupropion to schedule I.** Section 961.14 (2) (et), Stats., is created to read:

*961.14 (2) (et) Bupropion;*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register May 2021 No. 785, eff. 4–26–21; correction made under s. 35.17, Stats., Register May 2021 No. 785.

**CSB 2.82 Addition of Serdexmethylphenidate to schedule IV.** Section 961.20 (2m) (em), Stats., is created to read:

*961.20 (2m) (em) Serdexmethylphenidate.*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register July 2021 No. 787, eff. 7–12–21.

**CSB 2.83 Addition of ten (10) fentanyl-related substances to schedule I.** Section 961.14 (2) (nd) 21., 22., 23., 24., 25., 26., 27., 28., 29., and 30., Stats., is created to read:

*961.14 (2) (nd) 21. N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide (2'-fluoro ortho-fluorofentanyl; 2'-fluoro 2-fluorofentanyl);*

*22. N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide (4'-methyl acetyl fentanyl);*

*23. N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide ( $\beta$ -phenyl fentanyl; beta'-Phenyl fentanyl; 3-phenylpropanoyl fentanyl);*

*24. N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide ( $\beta$ -methyl fentanyl);*

*25. N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (ortho-fluorobutyryl fentanyl; 2-fluorobutyryl fentanyl);*

*26. N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide (ortho-methyl acetyl fentanyl; 2-methyl acetyl fentanyl);*

*27. 2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide (ortho-methyl methoxyacetyl fentanyl; 2-methyl methoxyacetyl fentanyl);*

*28. N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (para-methyl fentanyl; 4-methyl fentanyl);*

*29. N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide (phenyl fentanyl; benzoyl fentanyl);*

*30. N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide (thiofuranyl fentanyl; 2-thiofuranyl fentanyl; thiophene fentanyl).*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register July 2021 No. 787, eff. 7–19–21; correction made under s. 35.17, Stats., Register July 2021 No. 787.

**CSB 2.84 Addition of alfaxalone to schedule IV.** (1) Section 961.20 (2) (a), Stat., is repealed and recreated to read:

*961.20 (2) (a) Alfaxalone;*

(2) Section 961.20 (2) (ak) is created to read:

*961.20 (2) (ak) Alprazolam;*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register July 2021 No. 787, eff. 7–19–21; correction in numbering made under s. 13.92 (4) (b) 1, Stats., and correction made under s. 35.17, Stats., Register July 2021 No. 787.

**CSB 2.85 Excluding 6-beta-naltrexol from schedule II.** Section 961.16 (2) (a), Stats., is amended to read:

*961.16 (2) (a) Opium and substances derived from opium, and any salt, compound, derivative or preparation of opium or substances derived from opium. Apomorphine, dextrorphan, nalbuphine, butorphanol, naldemedine, nalmefene, naloxegol, naloxone, 6-beta-naltrexol, and naltrexone and their respective salts and the isoquinoline alkaloids of opium and their respective salts are excluded from this paragraph. The following substances, and any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register July 2021 No. 787, eff. 7–19–21; correction made under s. 35.17, Stats., Register July 2021 No. 787.

**CSB 2.86 Addition of fospropofol to schedule IV.** Section 961.20 (2) (en), Stats., is created to read:

*961.20 (2) (en) Fospropofol;*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register July 2021 No. 787, eff. 7–19–21; correction made under s. 35.17, Stats., Register July 2021 No. 787.

**CSB 2.87 Addition of embutramide to schedule III.** Section 961.18 (3) (bm), Stats., is created to read:

*961.18 (3) (bm) Embutramide;*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register July 2021 No. 787, eff. 7–19–21; correction made under s. 35.17, Stats., Register July 2021 No. 787.

**CSB 2.88 Addition of lacosamide to schedule V.** Section 961.22 (10), Stats., is created to read:

*961.22 (10) Lacosamide.*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register July 2021 No. 787, eff. 7–19–21.

**CSB 2.89 Addition of perampanel to schedule III.** Section 961.18 (3) (fm), Stats., is created to read:

*961.18 (3) (fm) Perampanel;*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register July 2021 No. 787, eff. 7–19–21; correction made under s. 35.17, Stats., Register July 2021 No. 787.

**CSB 2.90 Transfer of 1–phenylcyclohexylamine and 1–piperidinocyclohexanecarbonitrile, immediate precursors to phencyclidine, also known as PCP, from Schedule I to schedule II.** Section 961.16 (8) (c), Stats., is created to read:

*961.16 (8) (c) Immediate precursors to phencyclidine, also known as PCP:*

*1. 1–phenylcyclohexylamine.**2. 1–piperidinocyclohexanecarbonitrile.*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register July 2021 No. 787, eff. 7–19–21; correction made under s. 35.17, Stats., Register July 2021 No. 787.

**CSB 2.91 Addition of 4,4’–Dimethylaminorex to schedule I.** Section 961.14 (7) (cm), Stats., is created to read:

*961.14 (7) (cm) 4,4’–Dimethylaminorex.*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register September 2021 No. 789, eff. 9–27–21.

**CSB 2.92 Addition of thirty–eight (38) Anabolic Steroids to schedule III.** Section 961.18 (7), Stats., is repealed and recreated to read:

*961.18 (7) ANABOLIC STEROIDS. Unless specifically excepted or listed in another schedule, any material, compound, mixture, or preparation containing any quantity of any of the following anabolic steroids, including any of their esters, ethers, isomers, esters or ethers of isomers, salts and salts of esters or ethers, isomers and esters or ethers of isomers that are theoretically possible within the specific chemical designation, except that such terms do not include an anabolic steroid that is expressly intended for administration through implants to cattle or other nonhuman species and that has been approved by the secretary of health and human services for such administration, and if any person prescribes, dispenses, or distributes such steroid for human use, the person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this section:*

*(a) 3beta,17–dihydroxy–5alpha–androstane.**(ag) 3alpha,17beta–dihydroxy–5alpha–androstane.**(ar) 5alpha–androstane–3,17–dione.*

*(b) 1–androstenediol (3beta,17beta–dihydroxy–5alpha–androst–1–ene; 3alpha,17beta–dihydroxy–5alpha–androst–1–ene).*

*(bg) 4–androstenediol.**(br) 5–androstenediol.**(c) 1–androstenedione.**(cg) 4–androstenedione.**(cr) 5–androstenedione.**(d) Bolasterone.**(dg) Boldenone.**(dr) Boldione.**(e) Calusterone.**(eg) 4–chlorotestosterone, which is also called clostebol.**(er) Dehydrochloromethyltestosterone.**(f) Desoxymethyltestosterone.**(fg) Delta1–dihydrotestosterone.**(fr) 4–dihydrotestosterone, which is also called stanolone.**(g) Drostanolone.**(gg) Ethylestrenol.**(gr) Fluoxymesterone.**(h) Formebolone, which is also called fromebolone.**(hg) Furazabol.**(hr) 13beta–ethyl–17beta–hydroxygon–4–en–3–one.**(i) 4–hydroxytestosterone.**(ig) 4–hydroxy–19–nortestosterone.**(ir) Mestanolone.**(j) Mesterolone.**(jg) Methandienone, which is also called methandrostenolone.**(jr) Methandriol.**(k) Methasterone.**(kg) Methenolone.*

*(kr) 17alpha–methyl–3beta, 17beta–dihydroxy–5alpha–androstane.*

*(L) 17alpha–methyl–3alpha,17beta–dihydroxy–5alpha–androstane.*

*(Lg) 17alpha–methyl–3beta,17beta–dihydroxyandrost–4–ene.*

*(Lr) 17alpha–methyl–4–hydroxynandrolone.**(m) Methyldienolone.**(mg) Methyltestosterone.**(mr) Methyltrienolone.**(n) Mibolerone.*

*(ng) 17alpha–methyl–delta1–dihydrotestosterone, which is also called 17–alpha–methyl–1–testosterone.*

*(nr) Nandrolone.*

*(o) 19–nor–4–androstenediol (3beta, 17beta–dihydroxyestr–4–ene; 3alpha, 17beta–dihydroxyestr–4–ene).*

*(og) 19–nor–5–androstenediol (3beta, 17beta–dihydroxyestr–5–ene; 3alpha, 17beta–dihydroxyestr–5–ene).*

*(or) 19–nor–4,9(10)–androstadienedione.**(p) 19–nor–4–androstenedione (estr–4–en–3,17–dione).**(pg) 19–nor–5–androstenedione (estr–5–en–3,17–dione).**(pr) Norbolethone.**(q) Norclostebol.**(qg) Norethandrolone.**(qr) Normethandrolone.**(r) Oxandrolone.**(rg) Oxymesterone.**(rr) Oxymetholone.**(s) Prostanazol.**(sg) Stanozolol.**(sr) Stenbolone.**(t) Testolactone.**(tg) Testosterone.**(tr) Tetrahydrogestrinone.**(u) Trenbolone.*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register August 2022 No. 800, eff. 7–25–22; correction made under s. 35.17, Stats., Register August 2022 No. 800.

**CSB 2.93 Addition of Daridorexant to schedule IV.** Section 961.20 (2) (cpm), Stats., is created to read:

*961.20 (2) (cpm) Daridorexant;*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register August 2022 No. 800, eff. 7–25–22; correction made under s. 35.17, Stats., Register August 2022 No. 800.

**CSB 2.94 Addition of seven (7) synthetic benzimidazole–opioid substances to schedule I. (1)** Section 961.14 (2) (mm) and (pe), Stats., are renumbered to 961.14 (2) (xm) 3. and 5. and amended to read:

961.14 (2) (xm) 3. *Etonitazene (2-(2-(4-ethoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine).*

961.14 (2) (xm) 5. *Isotonitazene (N,N-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine).*

(2) Section 961.14 (2) (xm) (intro.) 1., 2., 4., and 6. to 9., Stats., are created to read:

961.14 (2) (xm) *Synthetic Benzimidazole–opioid Substances, specifically including all of the following:*

1. *Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine).*

2. *Etodesnitazene also known as Etazene (2-(2-(4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine).*

4. *Flunitazene (N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine).*

6. *Metodesnitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine).*

7. *Metonitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine).*

8. *N-pyrrolidino etonitazene also known as etonitazepyne (2-(4-ethoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole).*

9. *Protonitazene (N,N-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine).*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register August 2022 No. 800, eff. 7–25–22; correction in numbering of (1), (2) made under s. 13.92 (4) (b) 1., Stats., and correction in (1) made under s. 35.17, Stats., Register August 2022 No. 800.

**CSB 2.95 Addition of Ganaxolone to schedule V.** Section 961.22 (11), Stats., is created to read:

961.22 (11) GANAXOLONE. *Ganaxolone.*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register August 2022 No. 800, eff. 7–25–22; (title) created under s. 13.92 (4) (b) 2., Stats., Register August 2022 No. 800.

**CSB 2.96 Addition of Amineptine to schedule I.** Section 961.14 (7) (r), Stats., is created to read:

961.14 (7) (r) 7–[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid, commonly known as Amineptine.

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2023 No. 807, eff. 3–6–23; correction made under s. 35.17, Stats., Register March 2023 No. 807.

**CSB 2.97 Addition of Zipeprol to schedule I.** Section 961.14 (2) (zm), Stats., is created to read:

961.14 (2) (zm) *Zipeprol (1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol).*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2023 No. 807, eff. 3–6–23.

**CSB 2.98 Excluding [<sup>18</sup>F]FP–CIT from schedule II.** Section 961.16 (2) (b), Stats., is amended to read:

961.16 (2) (b) *Coca leaves and any salt, compound, derivative, or preparation of coca leaves. Decocainized coca leaves or extractions which do not contain cocaine or ecgonine are excluded from this paragraph. [<sup>125</sup>I]loflupane ~~is~~ and [<sup>18</sup>F]FP–CIT ~~are~~ excluded from this paragraph. The following substances and any of their salts, esters, isomers, and salts of esters and isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2023 No. 807, eff. 3–6–23.

**CSB 2.99 Addition of Mesocarb to schedule I.** Section 961.14 (7) (s), Stats., is created to read:

961.14 (7) (s) *N-phenyl-N'-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate, commonly known as Mesocarb.*

**History:** cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2023 No. 807, eff. 3–6–23.